share_log

ADC Therapeutics Analyst Ratings

ADC Therapeutics Analyst Ratings

ADC 治療分析師評級
Benzinga Analyst Ratings ·  2023/01/24 08:12
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
01/24/2023 5.76% Morgan Stanley $7 → $5 Maintains Equal-Weight
01/04/2023 323.06% HC Wainwright & Co. $21 → $20 Maintains Buy
11/14/2022 48.07% Morgan Stanley $11 → $7 Maintains Equal-Weight
11/09/2022 323.06% RBC Capital $25 → $20 Maintains Outperform
11/09/2022 48.07% B of A Securities $14 → $7 Downgrades Buy → Neutral
09/21/2022 5.76% JP Morgan → $5 Initiates Coverage On → Overweight
09/19/2022 344.21% HC Wainwright & Co. $20 → $21 Maintains Buy
09/09/2022 132.68% Morgan Stanley $17 → $11 Downgrades Overweight → Equal-Weight
08/22/2022 323.06% HC Wainwright & Co. $44 → $20 Maintains Buy
08/10/2022 513.43% RBC Capital $30 → $29 Maintains Outperform
07/11/2022 830.72% HC Wainwright & Co. $54 → $44 Maintains Buy
05/10/2022 259.6% Morgan Stanley $30 → $17 Maintains Overweight
05/10/2022 534.58% RBC Capital $34 → $30 Maintains Outperform
04/12/2022 534.58% Morgan Stanley $29 → $30 Maintains Overweight
03/04/2022 1042.25% HC Wainwright & Co. $55 → $54 Maintains Buy
02/01/2022 513.43% Morgan Stanley $47 → $29 Maintains Overweight
11/09/2021 830.72% Wolfe Research → $44 Initiates Coverage On → Outperform
11/03/2021 619.2% RBC Capital $33 → $34 Maintains Outperform
09/07/2021 894.18% Morgan Stanley $51 → $47 Maintains Overweight
08/09/2021 598.04% RBC Capital → $33 Initiates Coverage On → Outperform
07/16/2021 978.79% Morgan Stanley $53 → $51 Maintains Overweight
06/15/2021 873.03% Cantor Fitzgerald → $46 Initiates Coverage On → Overweight
05/14/2021 1063.41% HC Wainwright & Co. $57 → $55 Maintains Buy
05/10/2021 1021.1% Morgan Stanley $55 → $53 Maintains Overweight
04/26/2021 1105.71% HC Wainwright & Co. $48 → $57 Maintains Buy
03/23/2021 1063.41% Morgan Stanley $56 → $55 Maintains Overweight
03/19/2021 915.34% HC Wainwright & Co. $47 → $48 Maintains Buy
12/16/2020 1084.56% Morgan Stanley $52 → $56 Maintains Overweight
12/03/2020 788.42% Stifel → $42 Initiates Coverage On → Hold
10/29/2020 894.18% HC Wainwright & Co. → $47 Initiates Coverage On → Buy
10/13/2020 999.95% Morgan Stanley $53 → $52 Maintains Overweight
06/09/2020 1021.1% Morgan Stanley → $53 Initiates Coverage On → Overweight
06/09/2020 — Cowen & Co. Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
01/24/2023 5.76% 摩根士丹利 $7 → $5 維護 等重
01/04/2023 323.06% HC Wainwright公司 $21 → $20 維護 買
11/14/2022 48.07% 摩根士丹利 $11 → $7 維護 等重
11/09/2022 323.06% 加拿大皇家銀行資本 $25 → $20 維護 跑贏大盤
11/09/2022 48.07% B of A證券 $14 → $7 評級下調 購買→中性
09/21/2022 5.76% 摩根大通 → $5 開始承保 →超重
09/19/2022 344.21% HC Wainwright公司 $20 → $21 維護 買
09/09/2022 132.68% 摩根士丹利 $17 → $11 評級下調 超重→等重
08/22/2022 323.06% HC Wainwright公司 $44 → $20 維護 買
08/10/2022 513.43% 加拿大皇家銀行資本 $30 → $29 維護 跑贏大盤
07/11/2022 830.72% HC Wainwright公司 $54 → $44 維護 買
05/10/2022 259.6% 摩根士丹利 $30 → $17 維護 超重
05/10/2022 534.58% 加拿大皇家銀行資本 $34 → $30 維護 跑贏大盤
04/12/2022 534.58% 摩根士丹利 $29 → $30 維護 超重
03/04/2022 1042.25% HC Wainwright公司 $55 → $54 維護 買
02/01/2022 513.43% 摩根士丹利 $47 → $29 維護 超重
11/09/2021 830.72% 沃爾夫研究 → $44 開始承保 →跑贏大盤
11/03/2021 619.2% 加拿大皇家銀行資本 $33 → $34 維護 跑贏大盤
09/07/2021 894.18% 摩根士丹利 $51 → $47 維護 超重
08/09/2021 598.04% 加拿大皇家銀行資本 → $33 開始承保 →跑贏大盤
07/16/2021 978.79% 摩根士丹利 $53 → $51 維護 超重
06/15/2021 873.03% 康託·菲茨傑拉德 → $46 開始承保 →超重
05/14/2021 1063.41% HC Wainwright公司 $57 → $55 維護 買
05/10/2021 1021.1% 摩根士丹利 $55 → $53 維護 超重
04/26/2021 1105.71% HC Wainwright公司 $48 → $57 維護 買
03/23/2021 1063.41% 摩根士丹利 $56 → $55 維護 超重
03/19/2021 915.34% HC Wainwright公司 $47 → $48 維護 買
12/16/2020 1084.56% 摩根士丹利 $52 → $56 維護 超重
12/03/2020 788.42% Stifel → $42 開始承保 →保留
10/29/2020 894.18% HC Wainwright公司 → $47 開始承保 →購買
10/13/2020 999.95% 摩根士丹利 $53 → $52 維護 超重
06/09/2020 1021.1% 摩根士丹利 → $53 開始承保 →超重
06/09/2020 — 考恩公司 開始承保 →跑贏大盤

What is the target price for ADC Therapeutics (ADCT)?

ADC治療公司(ADCT)的目標價格是多少？

There is no price target for ADC Therapeutics

ADC治療公司沒有價格目標

What is the most recent analyst rating for ADC Therapeutics (ADCT)?

ADC治療公司(ADCT)的最新分析師評級是多少？

There is no analyst for ADC Therapeutics

ADC治療公司沒有分析師

When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?

ADC治療公司(ADCT)的下一次分析師評級將於何時發佈或更新？

There is no next analyst rating for ADC Therapeutics

ADC治療公司沒有下一個分析師評級

Is the Analyst Rating ADC Therapeutics (ADCT) correct?

分析師對ADC治療公司(ADCT)的評級正確嗎？

There is no next analyst rating for ADC Therapeutics

ADC治療公司沒有下一個分析師評級

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論